Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Lymphoma, T-Cell, Cutaneous 1

Interventions

fludarabine phosphate 6Peripheral Blood Stem Cell Transplantation 5Rituximab 4Mycophenolic Acid 4Cyclosporine 4Cyclophosphamide 4romidepsin 3Whole-Body Irradiation 3Methotrexate 3Everolimus 3Busulfan 3durvalumab 2Vorinostat 2Vincristine 2Tacrolimus 2Photopheresis 2Immunoglobulin G 2Filgrastim 2Etoposide 2Disulfides 2Brentuximab Vedotin 2Bortezomib 2veliparib 1tremelimumab 1tazarotenic acid 1tazarotene 1poly ICLC 1pembrolizumab 1navitoclax 1mogamulizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Lymphoma, T-Cell, Cutaneous × tazarotene × Clear all
NCT00779896 2008-10-24

Tazarotene 0.1% Cream For the Treatment of Cutaneous T-Cell Lymphoma: A Prospective Study

McGill University

Phase 1/2 Unknown
15 enrolled
DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡